Alembic Pharma Q3 Review - Dolat Capital Maintains 'Reduce' On The Stock, Revises Target Price — Here's Why

With limited upside, the brokerage maintains ‘Reduce’ rating with revised target price of Rs 1,004 at 22 times FY27E P/E.